RESUMO
The simultaneous occurrence of thyrotoxicosis and renal failure has rarely been reported in the literature, and data concerning appropriate antithyroid drug management in this circumstance are limited. We studied propylthiouracil pharmacokinetics in one such patient basally and while the patient was receiving hemodialysis. On a day when the patient was not receiving hemodialysis, propylthiouracil serum levels were high, but serum propylthiouracil half-life was not prolonged. During hemodialysis, serum propylthiouracil levels were normal, and the time to peak serum levels was delayed; the disappearance of the drug from the serum was normal after hemodialysis was completed. The amount of propylthiouracil that appeared in the dialysate was approximately 5% of the administered dose. These data suggest that propylthiouracil can be administered in standard dosages to patients with thyrotoxicosis and renal failure.
Assuntos
Falência Renal Crônica/sangue , Propiltiouracila/sangue , Tireotoxicose/tratamento farmacológico , Adulto , Feminino , Meia-Vida , Humanos , Falência Renal Crônica/complicações , Cinética , Diálise Renal , Tireotoxicose/complicaçõesRESUMO
We studied the effect of yohimbine, a drug that inhibits presynaptic alpha 2-adrenergic receptors and increases the neuronal release of norepinephrine from the central and sympathetic nervous systems, on tolerance to cardiovascular stress in 10 untrained, healthy subjects. Using radioligand binding of tritiated yohimbine to platelets, these subjects were found to have a normal complement of alpha 2-adrenergic receptors (174 +/- 18 [+/- SEM] receptors/platelet) with normal Kd (1.93 +/- 0.17 nmol/l). Lower body negative pressure was used to test responses to cardiovascular stress in the subjects after they received either placebo or 20 mg yohimbine. Graded lower body negative pressure from 0 to -40 mm Hg significantly decreased systolic blood pressure from 116 +/- 3.7 to 106 +/- 5.8 mm Hg, increased heart rate from 54 +/- 3 to 68 +/- 7 beats/min, decreased forearm blood flow from 1.8 +/- 0.21 to 1.36 +/- 0.25 ml/100 ml/min, and increased forearm vascular resistance from 55.76 +/- 12.1 to 77.26 +/- 15.8 mm Hg/ml/min. Yohimbine increased the blood pressure at rest and during lower body negative pressure, but these changes were not significantly different from values recorded from the individuals when they were given placebo. Compared with placebo, however, yohimbine significantly increased forearm blood flow at rest (1.80 +/- 0.21 vs. 2.66 +/- 0.31 ml/100 ml/min, p less than 0.05) and during -40 mm Hg of lower body negative pressure (1.36 +/- 0.25 vs. 1.91 +/- 0.28 ml/100 ml/min, p less than 0.05). We also found that yohimbine significantly increased the plasma insulin concentration in these fasted subjects (9.4 +/- 2.4 vs. 14.5 +/- 1.4 ng/ml, p less than 0.05) without inducing hypoglycemia.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Antagonistas Adrenérgicos alfa/farmacologia , Sistema Cardiovascular/fisiopatologia , Gravitação , Hipotensão Ortostática/fisiopatologia , Ioimbina/farmacologia , Adulto , Pressão Sanguínea/efeitos dos fármacos , Feminino , Antebraço/irrigação sanguínea , Humanos , Pressão Negativa da Região Corporal Inferior , Masculino , Pessoa de Meia-Idade , Norepinefrina/sangue , Receptores Adrenérgicos alfa/metabolismo , Fluxo Sanguíneo Regional , DescansoRESUMO
The effect of oral nifedipine on cerebral blood flow velocity was studied in six elderly hypertensive patients using transcranial Doppler. Serial measurements of blood pressure (BP), middle cerebral artery (MCA) flow velocity and nifedipine serum concentrations were obtained over an 8-hour period. The authors found a significant inverse relationship between MCA velocities and nifedipine concentrations, independent of BP changes. These results are consistent with a direct vasodilatory effect of nifedipine on cerebral vessels and support the use of TCD in pharmacodynamic investigations of the cerebral vasculature.
Assuntos
Circulação Cerebrovascular/efeitos dos fármacos , Hipertensão/diagnóstico por imagem , Nifedipino/farmacologia , Idoso , Velocidade do Fluxo Sanguíneo/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Feminino , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Nifedipino/administração & dosagem , Nifedipino/sangue , Nifedipino/uso terapêutico , UltrassonografiaAssuntos
Ciclosporinas/efeitos adversos , Hipertensão/etiologia , Receptores Adrenérgicos alfa/sangue , Plaquetas/metabolismo , Catecolaminas/sangue , Insuficiência Cardíaca/fisiopatologia , Transplante de Coração , Hipertensão/fisiopatologia , Transplante de Rim , Sistema Nervoso Simpático/fisiopatologia , Ioimbina/farmacologiaRESUMO
INTRODUCTION: Calcineurin inhibitors (CNI) have brought dramatic improvements in early renal allograft survival. However, CNI are associated with posttransplant hypertension (PTHTN), a risk factor for mortality from cardiovascular disease and graft failure. Sirolimus (SRL) is emerging as an alternative to CNI. SRL effects on blood pressure (BP) in humans are unclear. We compared the prevalence of PTHTN among patients receiving SRL as maintenance immunosuppression with a group receiving CNI by using 24-hour ambulatory BP (AMBP). AMBP has been shown to predict cardiovascular events and progression of kidney disease better than casual office BP measurements in chronic kidney disease (CKD) patients. METHODS: Renal transplant recipients with office hypertension (defined as BP > 130/80 or on antihypertensive medications), receiving stable immunosuppression and displaying consistent serum creatinine values for > or =6 months were eligible. We enrolled the first 40 patients to consent. Office BP was measured twice using a BP-Tru machine. AMBP was then analyzed for systolic BP (SBP), diastolic BP (DBP), and nocturnal blood pressure fall (NF; "dipping"). Patients were placed in the SRL group (n = 18) and the CNI group (n = 20) based on their maintenance immunosuppressive protocol. Two patients were excluded because of incomplete data. All patients received mycophenolate mofetil, and 14/38, maintenance steroids. We collected, demographics as well as type and date of renal allograft, medications, comorbidities, CKD stage, proteinuria, and plasma creatinine at the time of study enrollment. RESULTS: Patients in the SRL group displayed lower 24-hour SBP than the CNI group (128.0 +/- 10.8 vs 137.7 +/- 14; P = .029). Nightime MAP, nightime SBP, and nighttime DBP were all lower in the SRL group. NF did not reach significance between the SRL and CNI groups (44% vs 15%; P = .074). Patient demographics and number of antihypertensive medications did not differ. CONCLUSION: The lower 24-hour SBP seen in the SRL group by AMBP may lead to improved cardiovascular and renal outcomes over time. Long-term patient follow-up will be needed to clarify the effect of the lower 24-hour SBP.
Assuntos
Pressão Sanguínea/fisiologia , Calcineurina/efeitos adversos , Terapia de Imunossupressão/métodos , Transplante de Rim/fisiologia , Sirolimo/uso terapêutico , Adulto , Idoso , Anti-Hipertensivos/uso terapêutico , Índice de Massa Corporal , Cadáver , Doenças Cardiovasculares/mortalidade , Doenças Cardiovasculares/prevenção & controle , Nefropatias Diabéticas/cirurgia , Feminino , Humanos , Hipertensão/mortalidade , Hipertensão/prevenção & controle , Hipertensão/cirurgia , Falência Renal Crônica/etiologia , Falência Renal Crônica/cirurgia , Transplante de Rim/imunologia , Doadores Vivos/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Monitorização Ambulatorial/métodos , Complicações Pós-Operatórias/mortalidade , Complicações Pós-Operatórias/prevenção & controle , Período Pós-Operatório , Doadores de Tecidos/estatística & dados numéricosRESUMO
Coexistence of the two conditions may be coincidental, so the first step is to rule out nonrenal causes. Overall, the two most common causes are diuretic therapy and primary aldosteronism. New clinical insights regarding three other conditions--glucocorticoid-remediable aldosteronism, apparent mineralocorticoid excess, and deoxycorticosterone hypersecretion syndrome--are also discussed.
Assuntos
Hipertensão/etiologia , Hipopotassemia/etiologia , Humanos , Hiperaldosteronismo/diagnóstico , Hiperaldosteronismo/etiologia , Hiperaldosteronismo/metabolismo , Hipertensão/diagnóstico , Hipertensão/metabolismo , Hipopotassemia/diagnóstico , Hipopotassemia/metabolismo , Rim/metabolismo , Potássio/metabolismoRESUMO
We performed paired series of stop-flow studies on six mongrel dogs to determine a possible nephron site of action of synthetic atrial natriuretic factor (ANF). The initial free-flow response to intrarenal infusion of 5 micrograms/min of synthetic ANF into mannitol-expanded dogs resulted in an increased urine flow rate (6.81 +/- 0.88 to 9.00 +/- 1.17 ml/min, P less than 0.05) and a 40% increase in sodium excretion (496 +/- 110 to 694 +/- 166 meq/min, P less than 0.025) when compared to paired control periods. Renal blood flow did not change, but the glomerular filtration rate increased 4% (47 +/- 5 to 49 +/- 6 ml/min, P less than 0.05). The filtered load of sodium increased 4% (P less than 0.05), and the fractional sodium excretion increased by 35% (P less than 0.01). Stop-flow experiments showed no difference in tubular sodium concentration or in the fractional sodium-to-inulin ratio at the nadir of sodium concentration, suggesting that no differences existed in distal tubular sodium handling. Further, no apparent differences were detected in collections representing the more proximal portions of the nephron. While we were able to demonstrate marked natriuresis in response to synthetic ANF, no tubular effect was discernible, and the natriuresis obtained appears to be predominantly a function of hemodynamic effects.